AUS
NZ
UK
CA
USA
IND
Highlights:
-
RedHill Biopharma has secured funding from BARDA to advance the development of opaganib as a treatment for Ebola virus disease (EBOV).
-
Recent studies funded by the U.S. Army demonstrated that opaganib significantly improved survival rates in an EBOV model.
-
Opaganib is a novel drug with mutation-resistant antiviral and anti-inflammatory properties, being explored for multiple indications beyond Ebola, including COVID-19 and acute respiratory distress syndrome (ARDS).
Description:
RedHill Biopharma {NASDAQ:RDHL} has received funding from the U.S. government through the Biomedical Advanced Research and Development Authority (BARDA) to further develop opaganib as a medical countermeasure for Ebola virus disease (EBOV). This support will facilitate the advancement of opaganib, which has demonstrated promising results in recent studies aimed at addressing the urgent need for effective therapies for Ebola, a disease with a fatality rate of approximately 50%, according to the World Health Organization (WHO).
Opaganib is characterized as a novel and potentially broad-acting therapeutic agent with unique mutation-resistant antiviral and anti-inflammatory activities. Recent research, supported by the U.S. Army, has shown that opaganib significantly increases survival rates in animal models infected with the Ebola virus. These findings highlight the drug's potential as an effective treatment option in the face of the ongoing public health challenges posed by EBOV.
The need for viable and effective treatments for Ebola has intensified due to the virus's high fatality rate and the potential for outbreaks. Opaganib represents an alternative host-directed therapeutic strategy, enhancing biodefense efforts and contributing to global health preparedness. The drug is not only being developed for Ebola but is also being explored for several other indications, including COVID-19, acute respiratory distress syndrome (ARDS), and protection against radiological and chemical threats.
RedHill Biopharma’s strategic focus on opaganib positions the company at the forefront of innovative solutions for pressing health challenges. With BARDA’s backing, the advancement of opaganib could significantly contribute to the arsenal of medical countermeasures available for infectious diseases and enhance readiness for future health emergencies. This initiative underscores the importance of collaboration between public health authorities and biopharmaceutical companies in the quest for effective therapeutic solutions.
